Loading…
TPST
Tempest Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 87978U207
$1.06-1.85%Price as of Aug 29, 18:42 UTC · updated once a day, after the close
Key metrics
- Market cap
- $17.53M
- P/E
- —
- Forward P/E
- —
- P/B
- 18.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$3.61
- ROE
- -931.14%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -1.68
- 52-week high
- $12.23
- 52-week low
- $0.84
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.5% over 5Y.
today you would have $4.41▼ -99.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 14 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.87 | $10.85 | $57.20 | $14.95 | $68.64 | $417.30 | $1,314.30 | $1,550.25 | $4,095.00 | $4,475.25 | $28,577.25 | $129,343.50 | $26,734.50 | $24,482.25 | |
| P/S | 169.5x | — | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BCDABioCardia, Inc. | $1.15 | — | 6.4x | — | -1803.19% | $17.41M |
| LPCNLipocine Inc. | $2.17 | — | 0.8x | — | -60.94% | $17.89M |
| LEXXLexaria Bioscience Corp. | $10.35 | — | 3.6x | — | -162.77% | $17.1M |
| PMIPicard Medical, Inc. | $8.80 |
About the company
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
- 4
- Brisbane, United States
Company description provided by Yahoo Finance.